scholarly journals Fibroblast Growth Factor 23 (FGF-23) Concentrations in Cats with Early Nonazotemic Chronic Kidney Disease (CKD) and in Healthy Geriatric Cats

2013 ◽  
Vol 27 (2) ◽  
pp. 227-233 ◽  
Author(s):  
N.C. Finch ◽  
R.F. Geddes ◽  
H.M. Syme ◽  
J. Elliott
Keyword(s):  
Chronic Kidney Disease ◽  
Growth Factor ◽  
Kidney Disease ◽  
Fibroblast Growth Factor ◽  
Fibroblast Growth Factor 23 ◽  
Fibroblast Growth ◽  
Fgf 23

Role fibroblast growth factor-23 (FGF-23) in developmently of cardiorenal outcomes in chronic kidney disease stages III-V

2014 ◽  
Vol 20 (30) ◽  
pp. 36-41
Author(s):  
Дзгоева ◽  
Fatima Dzgoeva ◽  
Бестаева ◽  
Tamara Bestaeva ◽  
Сопоев ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Growth Factor ◽  
Kidney Disease ◽  
Fibroblast Growth Factor ◽  
Fibroblast Growth Factor 23 ◽  
Left Ventricular ◽  
Left Ventricular Geometry ◽  
Fibroblast Growth ◽  
Fgf 23 ◽  
Disease Stages

The aim of our study was to investigate the association of fibroblast growth factor 23 (FGF-23) with сardiorenal outcomes in chronic kidney disease stages III-V. FGF-23 was measured using commercially kits in 83 CKD stages III-V patients (40 females and 43 males aged 37-68 years). The patients were examined clinically with estimation of the levels of parathormone, calcium, phosphorus. Echocardiography on Aloka-4000 unit was made. Left ventricular geometry was assessed by J.Gottdiener classification. Therapeutic policy aimed of correction of anemia, arterial hypertension and phosphorus-calcium metabolism. FGF-23 correlated with renal function and weight of left ventricular hypertrophy. We have shown that changes in bone mediator and phosphate metabolism induced by CKD are independently associated with сardiorenal dysfunction.

scholarly journals Effect of Fibroblast Growth Factor-23 (FGF-23) on Two-Year Mortality Rate in Chronic Kidney Disease Patients With Hemodialysis

2021 ◽  
Vol 5 (2) ◽  
pp. 31-35
Author(s):  
Riri Andri Muzasti ◽  
Junita Tarigan
Keyword(s):  
Diabetes Mellitus ◽  
Chronic Kidney Disease ◽  
Growth Factor ◽  
Kidney Disease ◽  
Mortality Rate ◽  
Fibroblast Growth Factor ◽  
Fibroblast Growth Factor 23 ◽  
Dominant Factor ◽  
Fibroblast Growth ◽  
Fgf 23

Introduction Chronic kidney disease (CKD) is a global problem with increasing prevalence, poor prognosis, and high costs. Most deaths of CKD patients with hemodialysis (HD) is cardiovascular disorders. One of  risk factors related to cardiovascular disorder is Fibroblast Growth Factor-23 (FGF-23). FGF-23 level is associated with increased mortality in CKD patients with HD. Aim & Objectives The aim of this study is to show the effect of Fibroblast Growth Factor-23 (FGF-23 on two year mortality rate in chronic kidney disease patients with hemodialysis. Materials and Method This retro-prospective mixcohort study with survival analysis obtained data from medical records of CKD patients undergoing HD at the Rasyidah Renal Hospital in the first week of January 2018. Patients were followed up next two years until 31st of December 2019. Kaplan Meier analysis was used to determine the effect of independent variables on dependent variable that was two years mortality, multivariate cox regression analysis to determine the dominant factor and magnitude of the association between independent variable and dependent variable. P-value <0.05 indicates a significant association. Result Kaplan Meier curve showed significant effect of FGF-23 level and Diabetes Mellitus on a two-year survival rate of patients (p = 0.01 and p = 0.04). Based on cox regression multivariate analysis, it was found patients with FGF-23 levels> 365ng/ml had a risk of 3.53 (CI95% 1,104-11,337) times more than group of patients with FGF-23 ≤ 365ng/ml while the presence of diabetes mellitus was  risk factor on mortality with HR 3.71 (CI 1,279-10,796). Conclusion Statistically, FGF-23 level> 365 ng/ml is dominant factor that significantly influences 2-year mortality rate of CKD patients with HD other than Diabetes Mellitus. Key Words: Fibroblast Growth Factor, Chronic kidney disease on Hemodialysis, Mortality  

scholarly journals Relationship between Fibroblast Growth Factor-23 and Mineral Metabolism in Chronic Kidney Disease

2010 ◽  
Vol 2010 ◽  
pp. 1-7 ◽  
Author(s):  
Kosaku Nitta
Keyword(s):  
Chronic Kidney Disease ◽  
Growth Factor ◽  
Kidney Disease ◽  
Fibroblast Growth Factor ◽  
Fibroblast Growth Factor 23 ◽  
Left Ventricular ◽  
Serum Phosphate ◽  
Maintenance Hemodialysis ◽  
Fibroblast Growth ◽  
Fgf 23

Fibroblast growth factor- (FGF-)23 is a recently discovered regulator of calcium-phosphate metabolism. FGF-23 appears to decrease in synthesis and accelerated degradation of 1,25(OH)2D. Together with its cofactor Klotho, FGF-23 maintains serum phosphate levels within the normal range by increasing renal phosphate excretion. In chronic kidney disease (CKD), FGF-23 levels rise in parallel with the decline in renal function long before a significant increase in serum phosphate concentration occurs. Both Klotho and FGF-23, linked by a receptor mechanism, affect vitamin D synthesis and parathyroid hormone (PTH) secretion. Previous studies have shown a close association between reduced FGF-23 or Klotho activities and vascular calcification. The possible association of FGF-23 and left ventricular hypertrophy or vascular dysfunction has been proposed. Finally, prospective studies have shown that high serum FGF-23 concentrations predict more rapid disease progression in CKD patients who were not on dialysis and increased mortality in patients on maintenance hemodialysis. FGF-23 may therefore prove to be an important therapeutic target for the management of CKD.

scholarly journals Serum fibroblast growth factor 23 (FGF-23): associations with hyperphosphatemia and clinical staging of feline chronic kidney disease

2021 ◽  
pp. 104063872098556
Author(s):  
Jiabao Lin ◽  
Luqi Lin ◽  
Siyu Chen ◽  
Lifang Yu ◽  
Songjie Chen ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Growth Factor ◽  
Kidney Disease ◽  
Fibroblast Growth Factor ◽  
Fibroblast Growth Factor 23 ◽  
Age Groups ◽  
Clinical Staging ◽  
Fibroblast Growth ◽  
Ckd Stage ◽  
Fgf 23

Fibroblast growth factor 23 (FGF-23) is an independent monitor of the progression of chronic kidney disease (CKD) in human medicine, and FGF-23 may have value as a biomarker in feline CKD. We evaluated the relationship between serum FGF-23 and CKD stages, and the effect of age on FGF-23 in normal cats. We measured FGF-23 and intact parathyroid hormone (iPTH) concentrations by ELISA, with intra- and inter-assay CVs ≤ 15%. The percentage recovery of FGF-23 and iPTH remained stable for up to 7 d in samples stored at −20°C and −80°C. We measured FGF-23 in 304 cats, among which 196 were diagnosed with CKD. The 108 clinically healthy cats were divided into 5 subgroups based on growth stage (0–2 y, 3–6 y, 7–10 y, 11–14 y, ≥ 15 y). No statistical difference was found in FGF-23 among age groups ( p = 0.15) or by sex in healthy subjects. Using the International Renal Interest Society guideline, 34 cats were defined as CKD stage 1, 74 stage 2, 51 stage 3, and 37 stage 4. FGF-23 was higher in cats in all CKD stages than in controls. Higher serum phosphorus was observed in stage 3 ( p = 0.04) and 4 ( p < 0.01) compared to controls. iPTH increased as CKD progressed. Pearson analysis indicated a positive linear relationship between FGF-23 and iPTH (control: r = 0.70, p < 0.01; CKD: r = 0.46, p = 0.02). FGF-23 may be a useful biomarker of feline CKD and may precede hyperphosphatemia in advanced feline CKD.

scholarly journals GFR-Specific versus GFR-Agnostic Cutoffs for Parathyroid Hormone and Fibroblast Growth Factor-23 in Advanced Chronic Kidney Disease

2019 ◽  
Vol 50 (2) ◽  
pp. 105-114
Author(s):  
Mark Canney ◽  
Ognjenka Djurdjev ◽  
Mila Tang ◽  
Claudia Zierold ◽  
Frank Blocki ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Parathyroid Hormone ◽  
Growth Factor ◽  
Kidney Disease ◽  
Fibroblast Growth Factor ◽  
Fibroblast Growth Factor 23 ◽  
Reference Ranges ◽  
Fibroblast Growth ◽  
Advanced Chronic Kidney Disease ◽  
Fgf 23

Background: In the majority of patients with advanced chronic kidney disease (CKD), values of parathyroid hormone (PTH1–84) and fibroblast growth factor 23 (FGF-23) exceed the normal reference range, potentially as an appropriate adaptation to reduced glomerular filtration rate (GFR). We tested whether GFR-specific cutoffs for PTH1–84 and FGF-23 could better identify patients with inappropriately high PTH1–84 and FGF-23 for their degree of CKD and thereby improve prognostication of clinical outcomes compared to a uniform threshold. Methods: Prospective pan-Canadian cohort of 1,812 patients with mean estimated GFR (eGFR) 28.9 mL/min/1.73 m2 followed for a median of 52 months. Repeated log-rank tests were used to identify optimal cutoffs for PTH1–84 and FGF-23 within eGFR strata (<20, 20–29 and ≥30 mL/min/1.73 m2) that maximally differentiated high- and low-risk populations for (1) cardiovascular (CV) events (fatal or nonfatal myocardial infarction, coronary revascularization, stroke, heart failure) and (2) renal events (initiation of chronic renal replacement therapy). In multivariable models, we examined the association between ­GFR-specific cutoffs and outcomes and compared their added prognostic value to existing uniform thresholds. Results: Risk-based cutoffs for PTH1–84 and FGF-23 increased in a graded fashion with decreasing eGFR. Among patients with eGFR <20 mL/min/1.73 m2, CV risk-based cutoffs for PTH1–84 and FGF-23 were 3.4 and 5.5 times the upper limit of normal, respectively, and reclassified 31.9 and 35.1% of patients when added to a multivariable base model for CV events. In contrast, the addition of PTH1–84 and FGF-23 to the base model using uniform cutoffs failed to reclassify such patients. Similar findings were demonstrated for renal outcomes. Conclusion: GFR-specific risk-based cutoffs for PTH1–84 and FGF-23 may facilitate more meaningful risk stratification in advanced CKD than current GFR-agnostic reference ranges derived from healthy adults. This may be most applicable in those with severely reduced GFR.

scholarly journals Fibroblast growth factor 23 and lipid metabolism association in chronic kidney disease

2018 ◽  
pp. 34-40
Author(s):  
M. I. Chaikovska ◽  
L. P. Martynyuk
Keyword(s):  
Chronic Kidney Disease ◽  
Lipid Metabolism ◽  
Growth Factor ◽  
Kidney Disease ◽  
Total Cholesterol ◽  
Fibroblast Growth Factor ◽  
Fibroblast Growth Factor 23 ◽  
High Density Lipoproteins ◽  
Fibroblast Growth ◽  
Fgf 23

Recent scientificstudies have demonstrated the effect of fibroblast growth factor 23 (FGF-23) on the volume and distribution of body fat. The aim of our study was to investigate of lipid metabolism in patients with chronic kidney disease (CKD) and its relationship with FGF-23. Methods. We conducted a single-center, cohort retrospective study involved 106 patients with CKD 1-5 stages. Among the patients were 47 women (44%) and 59 men (56%) aged (49.6±13.9) years. All patients were determined the blood lipid spectrum: total cholesterol level (LDL), high density lipoproteins (HDL) and triglycerides (TG). The lipid profile was examined using a biochemical analyzer Cobas Integra 400 Plus. The C-terminal FGF-23 fragment was determined using a set of reagents for the enzyme immunoassay “Biomedica” (Astria). The glomerular filtration rate (GFR) was calculated using the CKD EPI formula (KDIGO 2012). All the statistical analyses were performed using Statistica 10.0. Results. In patients with CKD, progressive decrease in the level of total cholesterol, LDL cholesterol, HDL cholesterol and the increase in TG concurrent with the fall in GFR was detected (p<0.001). The concentration of the C-terminal FGF-23 fragment progressively increased in parallel with the fall in GFR, reaching the highest values at CKD stage 5 (p<0.001). A significant relationship was found between FGF-23 and total cholesterol (r =-0.45, p<0.05), LDL (r=-0.29, p<0.05), HDL (r=-0.54, p<0.05), FGF-23 and TG (r=0.28, p<0.05). Conclusions. CKD is characterized by a significant growth in TG levels, which increases with progression of renal dysfunction. The level of FGF-23 in CKD steadily increases in parallel with the decrease in GFR. The parameters of lipid metabolism, namely, total cholesterol, LDL, TG and HDL, have a reliable relationship with FGF-23 in CKD.

scholarly journals Fibroblast growth factor 23 (FGF-23) and chronic kidney disease in children

2021 ◽  
Vol 11-12 (221-222) ◽  
pp. 43-48
Author(s):  
Altynay Balmukhanova ◽  
◽  
Kairat Kabulbayev ◽  
Assiya Kanatbayeva ◽  
◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Growth Factor ◽  
Kidney Disease ◽  
Fibroblast Growth Factor ◽  
Fibroblast Growth Factor 23 ◽  
Healthy Children ◽  
Fibroblast Growth ◽  
Mineral Bone Disorder ◽  
Fgf 23 ◽  
Stage 1

Chronic kidney disease (CKD) in children is a complex medical and social problem in healthcare. One of the serious complications is mineral bone disorder (MBD), the pathogenesis of which is related to a new biomarker of bone origin - fibroblast growth factor 23 (FGF-23). The aim. To study the features of fibroblast growth factor 23 (FGF-23) in children with chronic kidney disease. Material and methods. A cross-sectional study was carried out on 73 children with CKD and 14 healthy children. Inclusion criteria: chronic kidney disease stage 1-5, written informed consent of the participants. The exclusion criteria: tubulopathy, infectious and inflammatory processes, oncological diseases, kidney transplant, condition after surgery, taking glucocorticosteroids, calcium and vitamin D drugs. We took fasting blood samples of participants and carried out an enzyme-linked immunosorbent assay in order determine the level of FGF-23 (Biomedica Medizinprodukte GmbH, Austria). The obtained data were analyzed using IBM SPSS, version 22 (New York, USA). Results and discussion. In healthy children, the median (Q1-Q3) level of FGF-23 in serum was 0.65 (0.22-0.98) pmol/l, in patients with stage 1 CKD it was 0.65 (0.22-1.08) pmol/l. At stage 2, the level of FGF-23 significantly increased in comparison with healthy individuals and with patients of stage 1, p≤0.05. Further, there is a gradual increase by stages, p≤0.05. Thus, in stage 3 patients, the median FGF-23 value was 1.9 (1.15-3.5) pmol/l, at stage 4 - 3.55 (2.48-6.35) pmol/l, at 5 stages - 14 (7.5-18.75) pmol/l. As a percentage, there were 7.1% of patients at the stage 1 with increased levels of phosphatonin, at stage 2 - 53.3%, at stage 3 - 69.2%, respectively. At stages 4 and 5, absolutely 100% of patients had high levels of FGF-23. At the same time, FGF-23 did not depend on gender, age, birth weight and type of renal replacement therapy at stage 5, p>0.05. Conclusions. Thus, in our study, we determined the features of changes FGF-23 in serum in children at various stages of CKD. The obtained results allow us to consider FGF-23 as a predictor of the clinical course of CKD. Keywords: fibroblast growth factor 23, phosphatonin, pediatric nephrology, chronic kidney disease, mineral-bone disorder.

Sign in / Sign up

Export Citation Format

Share Document